Bank of New York Mellon Corp Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Bank of New York Mellon Corp increased its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 7.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 93,997 shares of the company’s stock after purchasing an additional 6,430 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.40% of UroGen Pharma worth $1,001,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in URGN. RTW Investments LP boosted its stake in shares of UroGen Pharma by 6.5% in the 3rd quarter. RTW Investments LP now owns 3,787,347 shares of the company’s stock worth $48,099,000 after buying an additional 230,000 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in UroGen Pharma by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company’s stock worth $17,032,000 after acquiring an additional 21,072 shares during the period. State Street Corp boosted its holdings in shares of UroGen Pharma by 5.9% in the 3rd quarter. State Street Corp now owns 769,583 shares of the company’s stock worth $9,774,000 after buying an additional 42,907 shares during the last quarter. Geode Capital Management LLC boosted its stake in UroGen Pharma by 8.1% in the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after acquiring an additional 34,248 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new position in UroGen Pharma in the third quarter valued at approximately $5,080,000. 91.29% of the stock is owned by institutional investors.

Insider Buying and Selling

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

UroGen Pharma Trading Down 1.9 %

UroGen Pharma stock opened at $11.90 on Tuesday. The stock has a market cap of $548.52 million, a P/E ratio of -3.78 and a beta of 1.12. UroGen Pharma Ltd. has a fifty-two week low of $9.03 and a fifty-two week high of $20.70. The firm’s fifty day moving average price is $10.57 and its 200-day moving average price is $11.54. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Equities research analysts forecast that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on URGN shares. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Monday, March 10th. HC Wainwright lowered their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $38.20.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.